Radiotherapy Offers New Treatment Option for Liver Cancer
CancerConnect News: A novel technique that delivers high doses of radiation to tumors while sparing the surrounding normal tissue shows […]
CancerConnect News: A novel technique that delivers high doses of radiation to tumors while sparing the surrounding normal tissue shows […]
CancerConnect News: The Food and Drug Administration granted approvals to Opdivo (nivolumab) and Yervoy (ipilimumab) in combination for the treatment […]
CancerConnect News: The United States Food and Drug Administration (FDA) has approved the kinase inhibitor Cabometyx™ (cabozantinib) for the treatment […]
If you have children in your life, you already know that they tend to be creatures of habit who rely […]
The US Food and Drug Administration has approved Sutent (sunitinib malate) for the adjuvant treatment of adult patients at high […]
Opdivo (nivolumab) a novel “checkpoint” inhibitor immunotherapy has been demonstrated to produce superior three year survival benefit for patients with […]
Mvasi, a biosimilar to the cancer drug Avastin, is approved for certain colorectal, lung, brain, kidney and cervical cancers The […]
A Phase 3 study evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) in patients with previously untreated advanced or metastatic renal cell […]
A new study from Roswell Park Cancer Institute reporting the findings of the first clinical trial to evaluate the immune […]
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CB-839 in combination with afinitor® (everolimus), for […]
The results of a mid-stage clinical trial combining the IDO inhibitor epacadostat with the anti-PD-1 drug Keytruda (pembrolizumab) to be […]
A handful of drugs recently developed and approved by the United States Food and Drug Administration are expanding the emerging […]
The combination of Inlyta (axitinib) and dalantercept, an activin receptor–like kinase 1 (ALK1) signaling inhibitor appears promising in the treatment […]
An experimental kidney cancer drug outperformed the standard first-line therapy for patients with metastatic disease who are considered at risk […]
The agent Cabometyx™ (cabozantinib) improves anti-cancer responses and time to cancer progression compared to Sutent® (sunitinib) when used as initial […]
Obesity almost always increases cancer risk and worsens outcomes, but researchers led by scientists at Dana-Farber Cancer Institute report that […]
Surgery to remove a cancerous kidney can often lengthen the lives of patients receiving targeted therapy for metastatic kidney cancer, but […]
The United States Food and Drug Administration (FDA) has approved Lenvima® (lenvatinib) for the treatment of kidney cancer. The approval […]